Acumen Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 8, 2023 and accepted by EDGAR at Aug 8, 2023, 16:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-04-01 to 2023-06-30 | $9.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $17.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$13.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$26.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$11.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$22.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$0.56 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$0.56 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 41,025,062 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 41,025,062 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$21.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $0 | us-gaap:PaymentsToAcquireProductiveAssets |
| Current assets | At period end2023-06-30 | $149.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $177.4m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $8.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $8.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $168.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001576885-23-000050. Last ingested by Listed: Nov 5, 2026, 16:24 ET. Listed shows no prices and gives no investment advice.